Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

Summary

The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults.

Timeline

Start

2007-06

Primary completion

2008-04

Completion

2008-04

Outcome

Met primary endpoint

registry analysis (superiority or other test); Active vs Placebo; p = 0.0007; Mean Difference (Final Values) -0.6 (95% CI -0.9 to -0.2); ANCOVA NCT00486291 ↗

Drugs

Indications